DrugPatentWatch Database Preview
Drugs in Development Information for GDC-0152
» See Plans and Pricing
What is the drug development status for GDC-0152?
GDC-0152 is an investigational drug.
There have been 176 clinical trials for GDC-0152.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
Summary for GDC-0152
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 17 |
| WIPO Patent Applications | 73 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2010-07-01) |
| Vendors | 22 |
Recent Clinical Trials for GDC-0152
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | National Cancer Institute (NCI) | Phase 1 |
| Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subj | Genentech, Inc. | Phase 1 |
| A Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | Hoffmann-La Roche | Phase 2 |
Clinical Trial Summary for GDC-0152
Top disease conditions for GDC-0152
Top clinical trial sponsors for GDC-0152
US Patents for GDC-0152
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
